Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$13.79 USD
0.00 (0.00%)
Updated May 7, 2024 04:00 PM ET
After-Market: $13.81 +0.02 (0.15%) 5:12 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PLRX 13.79 0.00(0.00%)
Will PLRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PLRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLRX
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
PLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Other News for PLRX
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
Pliant Therapeutics price target lowered by $9 at RBC Capital, here's why
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Johnson & Johnson (JNJ) and Hims & Hers Health (HIMS)
Optimistic Buy Rating for Pliant Therapeutics Amidst Strong Pipeline Progress and Potential Breakthroughs